Nuveen
VNDA icon

Nuveen’s Vanda Pharmaceuticals VNDA Stock Holding History

Nuveen’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$719K Hold
117,502
– – ﹤0.01% 3107
2026
Q1 		$812K Sell
117,502
-173,971
-60% -$1.34M ﹤0.01% 2669
2025
Q4 		$2.57M Buy
291,473
+120,428
+70% +$663K ﹤0.01% 2184
2025
Q3 		$854K Buy
171,045
+47,690
+39% +$221K ﹤0.01% 2694
2025
Q2 		$582K Sell
123,355
-317,206
-72% -$1.39M ﹤0.01% 2832
2025
Q1 		$2.02M Buy
440,561
+285,811
+185% +$1.33M ﹤0.01% 2334
2024
Q4 		$741K Hold
154,750
– – ﹤0.01% 2832
2024
Q3 		$726K Sell
154,750
-372,073
-71% -$1.99M ﹤0.01% 2884
2024
Q2 		$2.98M Buy
526,823
+224,173
+74% +$1.16M ﹤0.01% 2190
2024
Q1 		$1.24M Buy
302,650
+147,900
+96% +$592K ﹤0.01% 2612
2023
Q4 		$653K Buy
154,750
+1,436
+0.9% +$5.79K ﹤0.01% 2919
2023
Q3 		$662K Sell
153,314
-246,689
-62% -$1.37M ﹤0.01% 2743
2023
Q2 		$2.64M Sell
400,003
-193,685
-33% -$1.24M ﹤0.01% 2228
2023
Q1 		$4.03M Buy
593,688
+21,073
+4% +$148K ﹤0.01% 2011
2022
Q4 		$4.23M Sell
572,615
-506,276
-47% -$4.93M ﹤0.01% 2004
2022
Q3 		$10.7M Buy
1,078,891
+91,106
+9% +$962K ﹤0.01% 1435
2022
Q2 		$10.8M Buy
987,785
+7,018
+0.7% +$72.7K ﹤0.01% 1455
2022
Q1 		$11.3M Sell
980,767
-15,601
-2% -$205K ﹤0.01% 1562
2021
Q4 		$15.6M Buy
996,368
+171,565
+21% +$2.99M ﹤0.01% 1386
2021
Q3 		$14.1M Buy
824,803
+588,107
+248% +$10.3M ﹤0.01% 1529
2021
Q2 		$5.09M Sell
236,696
-9,053
-4% -$162K ﹤0.01% 2238
2021
Q1 		$3.69M Sell
245,749
-6,389
-3% -$103K ﹤0.01% 2321
2020
Q4 		$3.31M Buy
252,138
+590
+0.2% +$7.1K ﹤0.01% 2263
2020
Q3 		$2.43M Sell
251,548
-22,896
-8% -$245K ﹤0.01% 2286
2020
Q2 		$3.14M Sell
274,444
-525,247
-66% -$5.95M ﹤0.01% 2133
2020
Q1 		$8.28M Sell
799,691
-220,168
-22% -$2.73M ﹤0.01% 1411
2019
Q4 		$16.7M Sell
1,019,859
-144,247
-12% -$2.18M 0.01% 1271
2019
Q3 		$15.5M Buy
1,164,106
+213,959
+23% +$2.98M 0.01% 1296
2019
Q2 		$13.4M Buy
+950,147
New +$15.1M 0.01% 1419

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's VNDA Position: Q2 2026 in Review

Nuveen held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 117,502 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #3107.

Nuveen first reported a position in VNDA in Q2 2019 and has held it in 29 quarters since. The position peaked at $16.7M in Q4 2019. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Nuveen held 117,502 shares of Vanda Pharmaceuticals worth $719K as of Q2 2026.
  • Nuveen left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3107 holding.
  • Nuveen first reported a position in Vanda Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Vanda Pharmaceuticals position peaked at $16.7M in Q4 2019.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.